Paul S. Gaynon

Dr. Paul S. Gaynon is a Professor of Pediatrics at the Keck School of Medicine, University of Southern California, and associated with Children’s Hospital Los Angeles (CHLA). His work focuses on pediatric hematology-oncology, particularly acute lymphoblastic leukemia (ALL) and its treatment. He has been a key contributor to clinical trials and therapeutic strategies through organizations like the Children’s Oncology Group (COG) and the Therapeutic Advances in Childhood Leukemia (TACL) consortium.

His research interests include relapse management, minimal residual disease surveillance, and novel therapies for refractory/relapsed leukemias. He has extensively studied treatment protocols for pediatric ALL, AML, and Hodgkin lymphoma, evaluating chemotherapy regimens and targeted agents like temsirolimus and decitabine.

Key contributions include defining treatment failure criteria, analyzing long-term outcomes for Down syndrome patients with ALL, and advancing protocols for T-cell ALL. His work bridges clinical practice and translational research, emphasizing evidence-based approaches to improve survival rates.

Dr. Gaynon’s involvement in multi-institutional trials has shaped pediatric oncology guidelines, particularly in high-risk and relapsed cases. His publications span over four decades, reflecting sustained contributions to improving outcomes for children with hematologic malignancies.